Brokerages Set Denali Therapeutics Inc. (NASDAQ:DNLI) Target Price at $35.00

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have been assigned a consensus recommendation of “Moderate Buy” from the sixteen research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, thirteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $35.00.

Several research firms recently commented on DNLI. HC Wainwright upped their price target on shares of Denali Therapeutics from $32.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Monday, April 20th. Jefferies Financial Group restated a “buy” rating and issued a $40.00 price target on shares of Denali Therapeutics in a research note on Monday, March 2nd. BTIG Research upped their price target on shares of Denali Therapeutics from $36.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. Finally, The Goldman Sachs Group upped their price target on shares of Denali Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, March 26th.

Denali Therapeutics Price Performance

Shares of DNLI opened at $20.43 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.16 and a quick ratio of 9.16. The company’s 50-day moving average is $20.22 and its 200-day moving average is $18.84. Denali Therapeutics has a fifty-two week low of $12.58 and a fifty-two week high of $23.77. The firm has a market capitalization of $3.24 billion, a PE ratio of -6.88 and a beta of 0.99.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.02. During the same quarter last year, the company earned ($0.67) earnings per share. Equities analysts forecast that Denali Therapeutics will post -2.86 EPS for the current year.

Hedge Funds Weigh In On Denali Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Foresite Capital Management VI LLC acquired a new stake in Denali Therapeutics during the third quarter worth about $14,520,000. AlphaQuest LLC grew its stake in Denali Therapeutics by 224.1% during the third quarter. AlphaQuest LLC now owns 74,422 shares of the company’s stock worth $1,081,000 after buying an additional 51,458 shares in the last quarter. Aberdeen Group plc grew its stake in Denali Therapeutics by 23.4% during the third quarter. Aberdeen Group plc now owns 1,113,586 shares of the company’s stock worth $16,169,000 after buying an additional 210,835 shares in the last quarter. Principal Financial Group Inc. grew its stake in Denali Therapeutics by 18.5% during the third quarter. Principal Financial Group Inc. now owns 1,271,190 shares of the company’s stock worth $18,458,000 after buying an additional 198,207 shares in the last quarter. Finally, Capricorn Fund Managers Ltd acquired a new stake in Denali Therapeutics during the fourth quarter worth about $1,027,000. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.